The pharmaceutical industry's demand for high-quality intermediates is ever-present, especially for complex molecules used in targeted therapies. ABT-199 Intermediate 2, scientifically known as tert-Butyl 4-Bromo-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzoate (CAS: 1628047-84-6), is a prime example of such a critical compound. Its essential role in the synthesis of Venetoclax (ABT-199) necessitates a focus on reliable sourcing and stringent quality control. This article provides insights from the manufacturer's perspective on procuring this vital component.

Understanding ABT-199 Intermediate 2

ABT-199 Intermediate 2 is characterized by its specific chemical structure and properties, including a molecular formula of C18H17BrN2O3 and a molecular weight of approximately 389.24 g/mol. It typically presents as a white powder, with a purity level crucial for successful downstream synthesis. Manufacturers aim for purity of 98.0% or higher, ensuring that the chemical reactions involved in creating Venetoclax proceed efficiently and without significant byproducts. The reliability of supply for such intermediates is as important as their quality, especially for companies involved in large-scale drug production.

The Manufacturer's Role in Quality Assurance

For manufacturers of pharmaceutical intermediates, quality assurance is not merely a procedural step but a fundamental commitment. Producing ABT-199 Intermediate 2 involves precise synthetic routes and rigorous analytical testing at various stages. Advanced manufacturers employ state-of-the-art equipment and adhere to strict quality management systems to guarantee the purity, consistency, and stability of each batch. When you buy this intermediate, understanding the manufacturer's quality control protocols, their capacity for batch-to-batch consistency, and their ability to provide comprehensive documentation (such as CoAs) is paramount.

Navigating the Procurement Process: What to Look For

When sourcing CAS 1628047-84-6, pharmaceutical companies should seek manufacturers who offer a combination of high-quality products, competitive pricing, and reliable logistics. Establishing a direct relationship with a reputable manufacturer, especially those based in China with established chemical production infrastructure, can offer significant advantages. Key aspects to consider include:

  • Purity Guarantee: Ensuring a minimum purity of 98.0% or higher.
  • Production Capacity: Ability to supply in required volumes, from kilos to tons.
  • Technical Support: Access to chemists for queries regarding synthesis or specifications.
  • Regulatory Compliance: Adherence to relevant industry standards.
  • Logistics and Packaging: Secure packaging and timely, reliable shipping.

By focusing on these points, buyers can build a robust supply chain and ensure the smooth progression of their Venetoclax manufacturing operations.

Conclusion

ABT-199 Intermediate 2 (CAS 1628047-84-6) is a vital component in modern cancer therapy. The expertise and commitment of manufacturers in producing this intermediate to high purity standards are essential. By diligently selecting suppliers based on quality, capacity, and reliability, pharmaceutical companies can secure their supply chains and contribute to the advancement of critical medical treatments.